Hidradenitis suppurativa as a chronic inflammatory disorder: are biological therapies the future therapeutic solution?

References

• Krbec AC. Current understanding and management of hidradenitis suppurativa. J. Am. Acad. Nurs. Pract.19(5), 228–234 (2007).
   PubMed Web of Science ®Google Scholar
• Wiseman M. Hidradenitis suppurativa: a review. Dermatol. Ther.17(1), 50–54 (2004).
   PubMedGoogle Scholar
• Plewig G, Kligman AM. Acne: Morphogenesis and Treatment. Springer-Verlag, Berlin, Germany (1975).
   Google Scholar
• Scheinfeld N. Hidradenitis should not be renamed acne inversa. Dermatol. Online J.12(7), 6 (2006).
   Google Scholar
• Bazex J, Bayle P, San B. Hidradenitis suppurativa is acne inversa. Int. J. Dermatol.46(3), 330 (2007).
   PubMed Web of Science ®Google Scholar
• von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br. J. Dermatol.144(4), 809–813 (2001).
   PubMed Web of Science ®Google Scholar
• Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J. Am. Acad. Dermatol.35(2 Pt 1), 191–194 (1996).
   PubMed Web of Science ®Google Scholar
• Jemec GBE. Medical treatment of hidradenitis suppurativa. Expert Opin. Pharmacother.5(8), 1767–1770 (2004).
   PubMed Web of Science ®Google Scholar
• Revuz JE, Canoui-Poitrine F, Wolkenstein P et al. Prevalence and factors associated with hidradenitis suppurativa: results form two case–control studies. J. Am. Acad. Dermatol.59(4), 695–601 (2008).
   Google Scholar
• Slade DEM, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br. J. Plast. Surg.56(5), 451–461 (2003).
   PubMedGoogle Scholar
• Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J. Am. Acad. Dermatol.56(4), 621–623 (2007).
   PubMed Web of Science ®Google Scholar
• Kurzen H, Kurokawa I, Jemec GBE et al. What causes hidradenitis suppurativa? Exp. Dermatol.17(5), 455–472 (2008).
   PubMed Web of Science ®Google Scholar
• Brook I, Frazier H. Aerobic and anaerobic microbiology of axillary hidradenitis suppurativa. J. Med. Microbiol.48(1), 103–105 (1999).
   PubMed Web of Science ®Google Scholar
• Sartorius K, Lapins J, Jalal S, Emtestam L, Hedberg M. Bacteraemia in patients with hidradenitis suppurativa undergoing carbon dioxide laser surgery: detection and quantification of bacteria by lysis-filtration. Dermatology213(4), 305–312 (2006).
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Hansen U. The histology of hidradenitis suppurativa. J. Am. Acad. Dermatol.34(6), 994–999 (1996).
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Thomsen BM, Hansen U. The homogeneity of hidradenitis suppurativa lesions. A histological study of intraindividual variation. APMIS105(5), 378–383 (1997).
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Jemec GBE. Lipid raft-enriched CD29+ keratinocytes in the epidermis, hair follicles and sinus tracts in hidradenitis suppurativa. Exp. Dermatol.13(6), 361–363 (2004).
   PubMed Web of Science ®Google Scholar
• Gao M, Wang P, Cui Y et al. Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p.21.1–1q25.3. J. Invest. Dermatol.126(6), 1302–1306 (2006).
   PubMed Web of Science ®Google Scholar
• Lapins J, Olerup O, Emtestam L. No human leukocyte antigen-A, -B or -DR association in Swedish patients with hidradenitis suppurativa. Acta Derm. Venereol.81(1), 28–30 (2001).
   PubMed Web of Science ®Google Scholar
• Barth JH, Kealey T. Androgen metabolism by isolated human axillary apocrine glands in hidradenitis suppurativa. Br. J. Dermatol.125(4), 304–308 (1991).
   PubMed Web of Science ®Google Scholar
• Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. Br. J. Dermatol.134(6), 1057–1059 (1996).
   PubMed Web of Science ®Google Scholar
• Arnadottir M, Jonsson E, Jonsson J. Inactivity of hidradenitis suppurativa after renal transplantation. Transplantation82(6), 849 (2006).
   PubMed Web of Science ®Google Scholar
• Lapins J, Asman B, Gustafsson A, Bergström K, Emtestam L. Neutrophil-related host response in hidradenitis suppurativa: a pilot study in patients with inactive disease. Acta Derm. Venereol.81(2), 96–99 (2001).
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br. J. Dermatol.156(1), 51–56 (2007).
   PubMed Web of Science ®Google Scholar
• Ather S, Chan D, Leaper D, Harding K. Surgical treatment of hidradenitis suppurativa: case series and review of the literature. Int. Wound J.3(3), 159–169 (2006).
   PubMedGoogle Scholar
• Sartorius K, Lapins J, Emstestam L, Jemec GBE. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br. J. Dermatol.149(1), 211–213 (2003).
   PubMed Web of Science ®Google Scholar
• Shah N. Hidradenitis suppurativa: a treatment challenge. Am. Fam. Physician72(8), 1547–1552 (2005).
   PubMed Web of Science ®Google Scholar
• Traczewski P, Rudnicka L. Adalimumab in dermatology. Br. J. Clin. Pharmacol.66(5), 618–625 (2008).
   PubMed Web of Science ®Google Scholar
• Mendonça CO, Griffiths CEM. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br. J. Dermatol.154(5), 977–978 (2006).
   PubMed Web of Science ®Google Scholar
• Friedel D, Climo M. Nasal colonization with methicillin-resistant Staphylococcus aureus: clinical implications and treatment. Curr. Infect. Dis. Rep.9(3), 201–207 (2007).
   PubMedGoogle Scholar
• Jemec GBE. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin. Exp. Dermatol.27(6), 528–529 (2002).
   PubMed Web of Science ®Google Scholar
• Joseph MA, Jayaseeelan E, Ganapathi B, Stephen J. Hidradenitis suppurativa treated with finasteride. J. Dermatol. Treat.16(2), 75–78 (2005).
   PubMed Web of Science ®Google Scholar
• Strauss RM, Pollock B, Stables GI, Goulden V, Cunliffe WJ. Photodynamic therapy using aminolaevullinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br. J. Dermatol.152(4), 803–804 (2005).
   PubMed Web of Science ®Google Scholar
• Kaur MR, Lewis HM. Hidradenitis suppurativa treated with daspone: a case series of five patients. J. Dermatol. Treat.17(4), 211–213 (2006).
   PubMed Web of Science ®Google Scholar
• Kagan RJ, Yakuboff KP, Warner P, Warden GD. Surgical treatment of hidradenitis suppurativa: a 10-year experience. Surgery138(4), 734–741 (2005).
   PubMed Web of Science ®Google Scholar
• Lapins J, Sartorius K, Emtestam L. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J. Am. Acad. Dermatol.47(2), 280–285 (2002).
   PubMed Web of Science ®Google Scholar
• Fardet l, Dupuy A, Kerob D et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J. Am. Acad. Dermatol.56(4), 624–628 (2007).
   PubMed Web of Science ®Google Scholar
• Brunaso AMG, Delfino C, Massone C. Hidradenitis suppurativa: are tumour necrosis factor-α blockers the ultimate alternative? Br. J. Dermatol.159(3), 761–763 (2008).
   PubMed Web of Science ®Google Scholar
• Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br. J. Dermatol.149(5), 1046–1049 (2003).
   PubMed Web of Science ®Google Scholar
• Usmani N, Clayton TH, Everett S, Goodfield DJ. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin. Exp. Dermatol.32(2), 204–205 (2007).
   PubMed Web of Science ®Google Scholar
• Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br. J. Dermatol.154(5), 1105–1108 (2006).
   Google Scholar
• Adams D, Gordon K, Devenyi A, Ioffreda M. Severe hidradenitis suppurativa treated with infliximab infusion. Arch. Dermatol.139(12), 1540–1542 (2007).
   Google Scholar
• Lebwohl B, Sapadin A. Infliximab for the treatment of hidradenitis suppurativa. J. Am. Acad. Dermatol.49(5), S275–S276 (2003).
   PubMed Web of Science ®Google Scholar
• Moul D, Korman N. The cutting edge. Severe hidradenitis suppurativa treated with adalimubab. Arch. Dermatol.142(9), 1110–1112 (2006).
   PubMedGoogle Scholar
• Scheinfeld N. Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimimab. J. Am. Acad. Dermatol.55(1), 163–164 (2006).
   PubMed Web of Science ®Google Scholar
• Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis. Br. J. Dermatol.154(4), 726–729 (2006).
   PubMed Web of Science ®Google Scholar
• Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br. J. Dermatol.158(2), 370–374 (2008).
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Pelekanou A, Antonopoulou A et al. An open-label Phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br. J. Dermatol.158(3), 567–572 (2008).
   PubMed Web of Science ®Google Scholar
• Striber BE, Kim C, Siu K. Efalizumab for the therapy of refractory hidradenitis suppurativa. J. Am. Acad. Dermatol.57(6), 1090–1091 (2007).
   PubMed Web of Science ®Google Scholar
• Lapins J, Ye W, Nyren O, Emtestam L. Incidence of cancer among patients with hidradenitia suppurativa. Arch. Dermatol.137(6), 730–734 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenzweig L, Brett A, Lefaivre J, Vandersteenhoven JJ. Hidradenitis suppurativa complicated by squamous cell carcinoma and paraneoplastic neuropathy. Am. J. Med. Sci.329(3), 150–152 (2005).
   PubMed Web of Science ®Google Scholar